Azetidine derivatives as CCR-3 receptor antagonists
US7288537B2 · kind B2 · utility
2Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2003 |
| Grant date | Oct 30, 2007 |
| Priority date | — |
| Expiry date | Jul 30, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of formula Iin free or salt form, wherein Ar, X, Y, R1, R2, R3, R5, m, n, p and q have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.